Blood Ocular Barrier (BOB)

The blood-ocular barrier (BOB) is not a single structure but two functionally distinct barriers — understanding which one is compromised in a given disease directly explains the clinical findings and guides treatment (e.g., why certain drugs reach the retina poorly, or why inflammation in one compartment doesn't necessarily mean the other is involved).

Blood-aqueous barrier

• Formed by the non-pigmented ciliary epithelium (tight junctions) and the endothelium of iris blood vessels
• Regulates what enters the aqueous humor from the ciliary body's blood supply and the iris vasculature
• Breakdown produces the classic signs of anterior segment inflammation: aqueous flare (protein leakage) and cells (inflammatory cells) in the anterior chamber — the basis of anterior chamber grading in uveitis
• Disrupted by intraocular surgery, trauma, and anterior uveitis

Blood-retinal barrier (inner and outer)

Why this distinction matters clinically

• Fluorescein angiography leakage patterns can localize which barrier has failed — helping distinguish, for example, a retinal vascular cause of edema (inner barrier) from an RPE-level cause (outer barrier)
• Systemic drug penetration into the eye depends heavily on which barrier a drug needs to cross — this partly explains why some systemically administered drugs reach the anterior segment more readily than the retina, and is part of the rationale for intravitreal (rather than oral/IV) delivery of many retinal therapeutics
• Breakdown of the blood-retinal barrier is a therapeutic target itself — anti-VEGF therapy works partly by reducing the vascular permeability that VEGF drives at the inner blood-retinal barrier